GRAIL Inc(GRAL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 4:15 PM ET (Korea 9/12 05:15)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -9.75 | Insider Own | 6.05% | Shs Outstand | 44.7M | Perf Week | -5.45% |
| Market Cap | 3.40B | Forward P/E | - | EPS next Y | -5.96% | Insider Trans | -8.32% | Shs Float | 42.0M | Perf Month | 10.57% |
| Enterprise Value | 2.63B | PEG | - | EPS next Q | -2.51 | Inst Own | 85.97% | Short Float | 20.29% | Perf Quarter | 26.71% |
| Income | -0.39B | P/S | 20.6 | EPS this Y | 13.36% | Inst Trans | 5.57% | Short Ratio | 13.52 | Perf Half Y | 71.92% |
| Sales | 0.17B | P/B | 1.34 | EPS next 5Y | 4.45% | ROA | -14.12% | Short Interest | 8.51M | Perf YTD | -10.94% |
| Book/sh | 56.93 | P/C | 3.95 | EPS past 3/5Y | 60.02% -41.05% | ROE | -16.12% | 52W High | -35.85% ($118.84) | Perf Year | 97.23% |
| Cash/sh | 19.29 | P/FCF | - | Sales past 3/5Y | 38.37% - | ROIC | -14.93% | 52W Low | 115.16% ($35.43) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 24.6% | Gross Margin | -36.99% | Volatility(W/M) | 4.22% 6.16% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 15.94 | Sales Y/Y TTM | 23.07% | Oper. Margin | -323.02% | ATR (14) | 4.38 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 10.74 | EPS Q/Q | 19.7% | Profit Margin | -236.95% | RSI (14) | 49.88 | Recom | 2.1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 10.95 | Sales Q/Q | 25.72% | SMA20 | -1.79% ($77.62) | Beta | 3.29 | Target Price | $77 |
| Payout | - | Debt/Eq | 0.04 | Earnings | 2026/8/5 | SMA50 | 4.04% ($73.27) | Rel Volume | 0.57 | Prev Close | $77.56 |
| Employees | 910 | LT Debt/Eq | 0.03 | EPS/Sales Surpr. | 3.6% 5.42% | SMA200 | 4.43% ($73) | Avg Volume(3M) | 0.63M | Price | $76.23 |
| IPO | 2024/6/12 | Option/Short | Yes/Yes | Trades | 8096 | Volume | 360,797 | Change | -1.71% |
Company
GRAL is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A US diagnostics company that develops and commercializes multi-cancer early detection tests. It develops and commercializes blood-based multi-cancer early detection tests, providing exposure to demand for early cancer detection and test adoption. The company operates in the multi-cancer early detection space.
Over the past 1 year, roughly in the middle
36% below its 1-year high.
GRAL has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth is moderate
Earnings are expected to grow by +13.4% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Short interest is a burden
Institutions hold 86.0%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
HTEC 0.02%
HELX 0.01%
XBI 0.01%
LABU 0.01%
SGRW 0.00%It ranks #4 in the industry
Based on market cap of $3B.
GRAL $3B PER -
TMO $225B PER 32.8
DHR $141B PER 35.5
NTRA $47B PER -
FAQ
What kind of company is GRAL?
GRAL belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of GRAL?
The market cap of GRAL is approximately $3.4B, ranking 1,687 within its sector.
What is the 52-week high and low for GRAL?
GRAL has recorded a 52-week high of $118.84 and a low of $35.43.
